protein

NATIVE INFLUENZA A H1N1 ANTIGEN

MBS239148

1 mL

465 USD

Antigen

NATIVE INFLUENZA A H1N1 ANTIGEN

INFLUENZA A H1N1 ANTIGEN

Inactivated Pathogen. Inactivated Influenza A H1N1 antigen - liquid.

Total protein concentration 1.26 mg/ml

Store at -70 degree C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Shelf Life: 18 months from date of despatch.

ELISA (EIA), Haemagglutination (H)

Source: Influenza strain A/California/7/2009/ NYMC X-179A (H1N1) cultured in embryonated chicken eggs. Preparation: Eggs are infected by injection into the allantoic chamber, incubated for 72 hours, and refrigerated overnight prior to harvest. Allantoic fluids are harvested from the eggs and pooled. The antigen preparation is inactivated by gamma radiation. Instructions For Use: A precipitate may form upon thawing, due to high product concentration. Dilute prior to clarification or other manipulation.

Activity: This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately. Target Species: Viral

Influenza is an acute infection of the respiratory tract caused by the Influenza virus, of which there are several different types. Influenza A causes flu in birds and some mammals and is the most virulent of the influenza types, resulting in the most severe disease. Influenza infection in humans causes chills, fever, pharyngitis, muscle pain, headaches, coughing and weakness. The virus is transmitted through the air by coughs or sneezes or through saliva, nasal secretions, faeces and blood. Infection may occur through direct contact with infected bodily fluid or contaminated surfaces. Influenza viruses mutate rapidly, making vaccines less effective from one season to the next. This particular strain of influenza is a reassortant virus that includes genetic components of the H1N1 influenza pandemic swine flu in a culture-adapted virus that has been selected for its qualities as a vaccine-producing strain. The live reassortant virus has passed safety testing in ferrets, in which it is attenuated for pathogenicity relative to wild-type A/California/4/2009 virus. Because A/California/4/2009 is identified as a variant strain of a pandemic virus, live derivatives must be handled under BSL2+ facilities and procedures. MBS239148 contains a high concentration of viral antigens as well as some egg proteins from allantoic fluid. Hemaglutination endpoint assay; 11,000 HA Units/ml

1 mL

465 USD